132 related articles for article (PubMed ID: 11755554)
1. Caffeine metabolism and the risk of spontaneous abortion of normal karyotype fetuses.
Signorello LB; Nordmark A; Granath F; Blot WJ; McLaughlin JK; Annerén G; Lundgren S; Ekbom A; Rane A; Cnattingius S
Obstet Gynecol; 2001 Dec; 98(6):1059-66. PubMed ID: 11755554
[TBL] [Abstract][Full Text] [Related]
2. Rate of caffeine metabolism and risk of spontaneous abortion.
Fenster L; Quale C; Hiatt RA; Wilson M; Windham GC; Benowitz NL
Am J Epidemiol; 1998 Mar; 147(5):503-10. PubMed ID: 9525538
[TBL] [Abstract][Full Text] [Related]
3. Caffeine, selected metabolic gene variants, and risk for neural tube defects.
Schmidt RJ; Romitti PA; Burns TL; Murray JC; Browne ML; Druschel CM; Olney RS;
Birth Defects Res A Clin Mol Teratol; 2010 Jul; 88(7):560-9. PubMed ID: 20641098
[TBL] [Abstract][Full Text] [Related]
4. NAT2 and CYP1A2 phenotyping with caffeine: head-to-head comparison of AFMU vs. AAMU in the urine metabolite ratios.
Nyéki A; Buclin T; Biollaz J; Decosterd LA
Br J Clin Pharmacol; 2003 Jan; 55(1):62-7. PubMed ID: 12534641
[TBL] [Abstract][Full Text] [Related]
5. Caffeine intake and the risk of first-trimester spontaneous abortion.
Cnattingius S; Signorello LB; Annerén G; Clausson B; Ekbom A; Ljunger E; Blot WJ; McLaughlin JK; Petersson G; Rane A; Granath F
N Engl J Med; 2000 Dec; 343(25):1839-45. PubMed ID: 11117975
[TBL] [Abstract][Full Text] [Related]
6. The effect of NAT2 genotype and gender on the metabolism of caffeine in nonsmoking subjects.
Welfare MR; Bassendine MF; Daly AK
Br J Clin Pharmacol; 2000 Mar; 49(3):240-3. PubMed ID: 10718779
[TBL] [Abstract][Full Text] [Related]
7. Coffee and tea consumption, genotype-based CYP1A2 and NAT2 activity and colorectal cancer risk-results from the EPIC cohort study.
Dik VK; Bueno-de-Mesquita HB; Van Oijen MG; Siersema PD; Uiterwaal CS; Van Gils CH; Van Duijnhoven FJ; Cauchi S; Yengo L; Froguel P; Overvad K; Bech BH; Tjønneland A; Olsen A; Boutron-Ruault MC; Racine A; Fagherazzi G; Kühn T; Campa D; Boeing H; Aleksandrova K; Trichopoulou A; Peppa E; Oikonomou E; Palli D; Grioni S; Vineis P; Tumino R; Panico S; Peeters PH; Weiderpass E; Engeset D; Braaten T; Dorronsoro M; Chirlaque MD; Sánchez MJ; Barricarte A; Zamora-Ros R; Argüelles M; Jirström K; Wallström P; Nilsson LM; Ljuslinder I; Travis RC; Khaw KT; Wareham N; Freisling H; Licaj I; Jenab M; Gunter MJ; Murphy N; Romaguera-Bosch D; Riboli E
Int J Cancer; 2014 Jul; 135(2):401-12. PubMed ID: 24318358
[TBL] [Abstract][Full Text] [Related]
8. Quantitation of three-month intraindividual variability and influence of sex and menstrual cycle phase on CYP1A2, N-acetyltransferase-2, and xanthine oxidase activity determined with caffeine phenotyping.
Kashuba AD; Bertino JS; Kearns GL; Leeder JS; James AW; Gotschall R; Nafziger AN
Clin Pharmacol Ther; 1998 May; 63(5):540-51. PubMed ID: 9630827
[TBL] [Abstract][Full Text] [Related]
9. The effect of pregnancy on cytochrome P4501A2, xanthine oxidase, and N-acetyltransferase activities in humans.
Tsutsumi K; Kotegawa T; Matsuki S; Tanaka Y; Ishii Y; Kodama Y; Kuranari M; Miyakawa I; Nakano S
Clin Pharmacol Ther; 2001 Aug; 70(2):121-5. PubMed ID: 11503005
[TBL] [Abstract][Full Text] [Related]
10. Analysis of within-subject variation of caffeine metabolism when used to determine cytochrome P4501A2 and N-acetyltransferase-2 activities.
McQuilkin SH; Nierenberg DW; Bresnick E
Cancer Epidemiol Biomarkers Prev; 1995 Mar; 4(2):139-46. PubMed ID: 7742721
[TBL] [Abstract][Full Text] [Related]
11. Cytochrome P4501A2 (CYP1A2) activity and lung cancer risk: a preliminary study among Chinese women in Singapore.
Seow A; Zhao B; Lee EJ; Poh WT; Teh M; Eng P; Wang YT; Tan WC; Lee HP
Carcinogenesis; 2001 Apr; 22(4):673-7. PubMed ID: 11285205
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of caffeine as a test drug for CYP1A2, NAT2 and CYP2E1 phenotyping in man by in vivo versus in vitro correlations.
Fuhr U; Rost KL; Engelhardt R; Sachs M; Liermann D; Belloc C; Beaune P; Janezic S; Grant D; Meyer UA; Staib AH
Pharmacogenetics; 1996 Apr; 6(2):159-76. PubMed ID: 9156694
[TBL] [Abstract][Full Text] [Related]
13. Caffeine consumption during pregnancy and spontaneous abortion.
Fenster L; Eskenazi B; Windham GC; Swan SH
Epidemiology; 1991 May; 2(3):168-74. PubMed ID: 2054397
[TBL] [Abstract][Full Text] [Related]
14. Xanthine oxidase inhibition by allopurinol affects the reliability of urinary caffeine metabolic ratios as markers for N-acetyltransferase 2 and CYP1A2 activities.
Fuchs P; Haefeli WE; Ledermann HR; Wenk M
Eur J Clin Pharmacol; 1999 Jan; 54(11):869-76. PubMed ID: 10027663
[TBL] [Abstract][Full Text] [Related]
15. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites.
Butler MA; Lang NP; Young JF; Caporaso NE; Vineis P; Hayes RB; Teitel CH; Massengill JP; Lawsen MF; Kadlubar FF
Pharmacogenetics; 1992 Jun; 2(3):116-27. PubMed ID: 1306111
[TBL] [Abstract][Full Text] [Related]
16. Foreign compound metabolism capacity in man measured from metabolites of dietary caffeine.
Vistisen K; Poulsen HE; Loft S
Carcinogenesis; 1992 Sep; 13(9):1561-8. PubMed ID: 1394840
[TBL] [Abstract][Full Text] [Related]
17. Cigarette, alcohol, and caffeine consumption: risk factors for spontaneous abortion.
Rasch V
Acta Obstet Gynecol Scand; 2003 Feb; 82(2):182-8. PubMed ID: 12648183
[TBL] [Abstract][Full Text] [Related]
18. Heterocyclic amine intake, smoking, cytochrome P450 1A2 and N-acetylation phenotypes, and risk of colorectal adenoma in a multiethnic population.
Voutsinas J; Wilkens LR; Franke A; Vogt TM; Yokochi LA; Decker R; Le Marchand L
Gut; 2013 Mar; 62(3):416-22. PubMed ID: 22628494
[TBL] [Abstract][Full Text] [Related]
19. A population phenotyping study of three drug-metabolizing enzymes in Kyushu, Japan, with use of the caffeine test.
Saruwatari J; Nakagawa K; Shindo J; Tajiri T; Fujieda M; Yamazaki H; Kamataki T; Ishizaki T
Clin Pharmacol Ther; 2002 Aug; 72(2):200-8. PubMed ID: 12189367
[TBL] [Abstract][Full Text] [Related]
20. Interaction of ibuprofen and probenecid with drug metabolizing enzyme phenotyping procedures using caffeine as the probe drug.
Vrtic F; Haefeli WE; Drewe J; Krähenbühl S; Wenk M
Br J Clin Pharmacol; 2003 Feb; 55(2):191-8. PubMed ID: 12580991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
